<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1509222612
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Dacepton
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APOMORPHINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C ,  protect from Light
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        890.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EVER PHARMA JENA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EVER PHARMA JENA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EVER Neuro Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N04BC07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Apomorphine hydrochloride hemihydrate belongs to a group of medicines known as dopamine agonists. Dacepton 5 mg/ml is used to treat Parkinson&rsquo;s disease. Apomorphine helps to reduce the amount of time spent in an &lsquo;off&rsquo; or immobile state in people who have previously been treated for Parkinson&rsquo;s disease with levodopa (another treatment for Parkinson&lsquo;s disease) and/or other dopamine agonists.</p><p dir="ltr">Your doctor &lt;or nurse&gt; will help you to recognise the signs of when to use your medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do NOT use Dacepton 5 mg/ml</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are under 18 years of age</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have breathing difficulties or suffer from asthma</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have dementia or Alzheimer&rsquo;s disease</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from confusion, hallucinations, or any other similar problems</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe dyskinesia (involuntary movements) or severe dystonia (inability to move) on account of the treatment with levodopa</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to apomorphine or any of the other ingredients of this medicine (listed in section 6).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or someone in your family are known to have an abnormality of electrocardiogram (ECG) called &ldquo;long QT syndrome&rdquo;. Tell your doctor.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Before you use Dacepton 5mg/ml your doctor will obtain an ECG (electrocardiogram) and will ask for a list of all other medicines you take. This ECG will be repeated in the first days of your treatment and at any point if your doctor thinks this is needed. He or she will also ask you about other diseases you may have, in particular concerning your heart. Some of the questions and investigations may be repeated at each medical visit. If you experience symptoms which may come from the heart, e.g. palpitations, fainting, or near-fainting, you should report this to your doctor immediately. Also if you experience diarrhoea or start a new medication, this should be reported to your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Talk to your doctor&lt;, nurse&gt; or pharmacist before using Dacepton 5 mg/ml:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have lung problems</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood pressure or feel faint and dizzy when you stand</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any medicines to treat high blood pressure</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you feel sick or suffer from being sick</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any mental disorders when Dacepton is started</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are elderly or frail</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when driving or operating machinery since apomorphine may cause sleepiness including sudden sleep onset episodes (you must not drive or operate machinery if Dacepton makes you sleepy)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor should check your body regularly when taking Dacepton with levodopa (another treatment for Parkinson&acute;s disease).</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to adjust or stop your dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Some patients develop addiction-like symptoms leading to craving for large doses of &nbsp;Dacepton 5mg/ml and other medicines used to treat Parkinson`s disease.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If any of the above situations applies to you, please inform your doctor or nurse.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Check with your doctor or pharmacist before taking your medicine if:</strong></p><p dir="ltr">You are using medicines that are known to affect the way your heart beats. This includes medicines used for heart rhythm problems (such as quinidine and amiodarone), for depression (including tricyclic antidepressants such as amitriptyline and imipramine) and for bacterial infections (&lsquo;macrolide&rsquo; antibiotics such as erythromycin, azithromycin and clarithomycin) and domperidone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other medicines and Dacepton 5 mg/ml</p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without prescription.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you use Dacepton 5 mg/ml with other medicines the effect of those medicines may be altered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">This is especially true for:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as clozapine to treat some mental disorders</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines to lower your blood pressure</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other medicines for Parkinson&lsquo;s disease</p><p dir="ltr">&nbsp;</p><p dir="ltr">Your doctor will tell you if you need to adjust the dose of your apomorphine or any of your other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are taking levodopa (another medicine for Parkinson&rsquo;s disease) as well as apomorphine your doctor should check your blood regularly.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Dacepton 5 mg/ml with food and drink</strong></p><p dir="ltr">Food and drink do not affect Dacepton 5 mg/ml.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Pregnancy and breast-feeding </strong></p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor&lt;, nurse&gt; or pharmacist for advice before taking this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml should not be used during pregnancy unless clearly necessary. Check with your doctor &lt;or nurse&gt; before using Dacepton 5 mg/ml if you are pregnant, think you may be pregnant or you are planning to become pregnant.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is not known whether Dacepton 5 mg/ml is transferred to breast milk. Talk to your doctor if you are breast-feeding or intend to breast-feed. Your doctor will explain to you, whether you should continue/discontinue breast-feeding or continue/discontinue taking this medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Driving and using machines</p><p dir="ltr">Dacepton 5 mg/ml can cause drowsiness and a strong desire to sleep. Do not drive or use any tools or machinery if Dacepton 5 mg/ml makes you sleepy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml contains<strong> sodium metabisulphite</strong> which may rarely cause severe hypersensitivity reactions and bronchospasm with symptoms such as rash or itchy skin, difficulty breathing, puffiness of the eyelids, face or lips, swelling or redness of the tongue. If you experience these side effects, immediately go to the nearest hospital casualty department.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml contains 3.4 mg sodium per ml. To be taken into consideration by patients on a controlled sodium diet</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always use this medicine exactly as your doctor has told you. Check with your doctor&lt;, nurse&gt; or pharmacist if you are not sure.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Before you use &lt;apomorphine&gt;, your doctor will ensure that you tolerate the medicine and an antiemetic medicine that you need to use simultaneously.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Do not use Dacepton 5 mg/ml if</strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution has turned green.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution is cloudy or you can see particles in it.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Where to inject your Dacepton 5 mg/ml</p><p dir="ltr">Inject your Dacepton 5 mg/ml into an area under the skin (subcutaneously) as shown by your doctor &lt;or nurse&gt;.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Do not inject Dacepton 5 mg/ml into a vein</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">How much to use</p><p dir="ltr">Both the amount of Dacepton 5 mg/ml you should use and the total amount of time you should receive your medicine each day, will depend upon your personal needs. Your doctor will discuss this with you and tell you how much of your medicine you should administer.</p><p dir="ltr">The amount that will work best for you will have been determined during your visit to the specialist clinic.</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The average infusion dose per hour is between 1 mg and 4 mg apomorphine hydrochloride.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Usually this is given to you when you are awake and generally stopped before you go to sleep.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The amount of apomorphine hydrochloride that you receive each day should not exceed 100mg</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor &lt;or nurse&gt; will decide which dose is best for you</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A different site for each infusion should be used every 12 hours.</p><p dir="ltr">&nbsp;</p><p dir="ltr">There is no need to dilute Dacepton before use. In addition, it should not be mixed with other medicines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton has been designed for continuous infusion with a minipump or syringe driver. It is not to be used for intermittent injection. The choice of which minipump and or syringe-driver to use, and the dosage settings required will be determined by the physician in accordance with the particular needs of the patient.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor &lt;or nurse&gt;.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you use more Dacepton 5 mg/ml than you should </strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or contact your nearest hospital emergency department immediately.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is important to administer the correct dose of Dacepton and not to use more than the amount recommended by your doctor. Higher doses may cause a slow heart rate, excessive sickness, excessive sleepiness and/or difficulty breathing. You may also feel faint or dizzy particularly when you stand up, due to low blood pressure. Lying down and raising your feet will help to treat low blood pressure.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you forget to use Dacepton 5 mg/ml</strong></p><p dir="ltr">Take it when you next require it. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>If you stop using Dacepton 5 mg/ml</strong></p><p dir="ltr">Contact your doctor before stopping treatment and discuss whether this appropriate or not.</p><p dir="ltr">If you have any further questions on the use of this medicine, ask your doctor&lt;, nurse&gt; or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor if you think your medicine is making you feel unwell or if you get any of the following:</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Very common side effects (may </u><u>affect more than 1 in 10 users):</u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lumps under the skin at the site of injection which are sore, troublesome and may be red and itchy. In order to avoid getting these lumps, it is advisable to change the site of injection every time you insert the needle.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucinations (seeing, hearing or feeling things that are not there)</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Common side effects (may affect up to 1 in 10 users):</u></p><p dir="ltr">Feeling sick or being sick, particularly when starting Dacepton 5 mg/ml. Domperidone should be started at least 2 days before Dacepton 5 mg/ml to stop you feeling or being sick.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lf you are taking domperidone and still feel sick, or if you are not taking domperidone and you have sickness, tell your doctor &lt;or nurse&gt; as soon as possible</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired or excessive sleepy</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion or hallucinations</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yawning</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy or light-headed when standing up</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Uncommon side effects (may affect up to 1 in 100 users): </u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased involuntary movements or increased shakiness during &lsquo;on&lsquo; periods</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemolytic anaemia, an abnormal breakdown of red blood cells in the blood vessels or elsewhere in the body. This is an uncommon side effect that can occur in patients also taking levodopa.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suddenly falling asleep</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rashes</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing difficulties</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site ulceration</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in red blood cells which can make the skin pale yellow and cause weakness or breathlessness</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in blood platelets, which increases the risk of bleeding or bruising</p><p dir="ltr"><u>&nbsp;</u></p><p dir="ltr"><u>Rare side effects (may affect up to 1 in 1000 users): </u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An allergic reaction such as difficulty breathing or tightness of the chest, puffiness of eyelids, face or lips, swelling or redness of the tongue</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eosinophilia, an abnormally high amount of white blood cells in the blood or in body tissues.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><u>Side effects with unknown frequency (frequency cannot be estimated from the available data):</u></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the legs, feet or fingers</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression, agitation</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:</p><p dir="ltr">&nbsp;</p><p dir="ltr">o&nbsp;&nbsp; Strong impulse to gamble excessively despite serious personal or family consequences.</p><p dir="ltr">o&nbsp;&nbsp; Altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive.</p><p dir="ltr">o&nbsp;&nbsp; Uncontrollable excessive shopping or spending</p><p dir="ltr">o&nbsp;&nbsp; binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Tell your doctor if you experience any of these behaviors; she or he will discuss ways of managing or reducing the symptoms</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">If you get any side effects, talk to your doctor&lt;, nurse&gt; or pharmacist. This includes any side effects not listed in this leaflet.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Reporting of side effects</strong></p><p dir="ltr">If you get any side effects, talk to your doctor or pharmacist &lt;or nurse&gt;. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the National Pharmacovigilance Centre (NPC):</p><p dir="ltr">- SFDA Call Center: 19999</p><p dir="ltr">- E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">- Website: https://ade.sfda.gov.sa/</p><p dir="ltr">&nbsp;</p><p dir="ltr">By reporting side effects you can help provide more information on the safety of this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&nbsp;</p><p dir="ltr">Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Keep the vial in the outer carton in order to protect from light.</p><p dir="ltr">Do not refrigerate or freeze.</p><p dir="ltr">&nbsp;</p><p dir="ltr">After opening and filling the drug product in syringes attached with infusion sets: chemical and physical in-use stability has been demonstrated for 7 days at 25 &deg;C.</p><p dir="ltr">From a microbiological point of view, unless the method of opening and further handling precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the carton and label after &ldquo;EXP.&rdquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use this medicine if you notice that the solution has turned green. It should only be used if the solution is clear, colourless to slightly yellow and free of particles.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Used syringes and needles should be discarded in a &lsquo;Sharps&rsquo; bin or other suitable container. When your &lsquo;Sharps&rsquo; bin or container is full, please give it to your doctor or pharmacist for safe disposal.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is apomorphine hydrochloride hemihydrate. Each millilitre of Dacepton 5 mg/ml contains 5 mg of apomorphine hydrochloride hemihydrate.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml is available in 20 ml vials containing 100 mg of apomorphine hydrochloride hemihydrate.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The other ingredients are:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium metabisulphite (E223)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochloric acid (for pH-adjustment)</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water for Injections</p><p dir="ltr">&nbsp;</p><p dir="ltr">Refer to &rsquo;Section 2: Dacepton 5 mg/ml contains metabisulphite and sodium chloride&rsquo; regarding sodium metabisulphite and sodium chloride.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Dacepton 5 mg/ml is a clear and colourless to slightly yellow solution for infusion.

Glass vials containing 20 ml solution for infusion, in packs of 1, 5 or 30 vials. 

Bundle packs: 5 x 1, 10 x 1, 30 x 1, 2 x 5 and 6 x 5

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>EVER Neuro Pharma GmbH</p><p>Oberburgau 3</p><p>4866 Unterach</p><p>Austria</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>EVER Neuro Pharma GmbH</p><p>Oberburgau 3</p><p>4866 Unterach</p><p>Austria</p><p>&nbsp;</p><p>EVER Pharma Jena GmbH</p><p>Otto-Schott-Strasse 15</p><p>07745 Jena</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in September 2022 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">آبومورفين هيدروكلوريد&nbsp;هيميهيدريت&nbsp;ينتمي إلى مجموعة من الأدوية&nbsp;المعروفة باسم طلائع الدوبامين.&nbsp;يستخدم داسيبتون 5&nbsp;مغم / مل&nbsp;لعلاج مرض باركنسون.&nbsp;يساعد الآبومورفين&nbsp;على&nbsp;تقليل كمية الوقت المستغرق في حالة السكون للأشخاص الذين سبق علاجهم من مرض باركنسون باستخدام دواء ليفودوبا (علاج آخر لمرض باركنسوس) و/أو غيرها من طلائع الدوبامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيساعدك&nbsp;طبيبك&nbsp;&lt;&nbsp;أو ممرضك &gt;&nbsp;على التعرف على الأعراض التي تستوجب معها استخدام الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الحالات التي لا يجوز فيها استخدام داسيبتون</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong></p><p dir="RTL">-&nbsp;إذا كان&nbsp;عمرك أقل من 18 عاماً.</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني من&nbsp;صعوبات في التنفس&nbsp;أو تعاني من الربو</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت تعاني من الخرف أو مرض الزهايمر</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت تعاني من&nbsp;الارتباك أو&nbsp;الهلوسة&nbsp;أو أي مشاكل أخرى مشابهة</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت تعاني من مشاكل في الكبد</p><p dir="RTL">-&nbsp;إذا كان&nbsp;لديك خلل حركي حاد (حركات لا إرادية) أو خلل شديد (عدم القدرة على الحركة)&nbsp;بسبب العلاج&nbsp;بدوا ليفودوبا</p><p dir="RTL">-&nbsp;إذا كان&nbsp;لديك حساسية من آبومورفين أو أي من المكونات الأخرى&nbsp;لهذا الدواء&nbsp;(&nbsp;المدرجة في&nbsp;القسم 6).</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت أنت أو أحد أفراد عائلتك يعاني من خلل في تخطيط&nbsp;كهربية القلب تسمى &quot;متلازمة كيو تي الطويلة&quot;&nbsp;فعليك إخبار طبيبك بذلك.</p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">قبل استخدام داسيبتون سيحصل طبيبك على مخطط كهربية القلب وسيطلب منك قائمة بجميع الأدوية الأخرى التي تتناولها.&nbsp;سوف يتكرر تخطيط القلب الكهربائي في الأيام الأولى من العلاج وفي أي لحظة إذا كان طبيبك يعتقد أنه ضرورياً.&nbsp;سوف يسألك عن أمراض أخرى قد تعاني منها وبخاصة فيما يتعلق بقلبك.&nbsp;قد تتكرر بعض الأسئلة والاستفسارات في كل زيارة طبية.&nbsp;إذا كنت تعاني من أعراض قد تأتي من القلب، على سبيل المثال خفقان القلب أو الإغماء أو شبه الإغماء، فيجب عليك إبلاغ الطبيب بذلك على الفور.&nbsp;إذا كنت تعاني كذلك من الإسهال أو البدء بتعاطي دواءً جديداً، فيجب إبلاغ الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك&nbsp;&lt;ممرضك&gt;&nbsp;أو&nbsp;الصيدلاني&nbsp;قبل&nbsp;استخدام داسيبتون 5 ملغم / مل:</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني من مشاكل في الكلى</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني من مشاكل في الرئة</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت&nbsp;تعاني من مشاكل في القلب</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت تعاني من&nbsp;انخفاض في ضغط الدم أو الشعور بالإغماء والدوار عند الوقوف</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت&nbsp;تأخذ أي أدوية لعلاج ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت تشعر بأعراض مرضية أو&nbsp;كنت&nbsp;تعاني من مرض</p><p dir="RTL">-&nbsp;إذا كان&nbsp;لديك أي اضطرابات عقلية عند بدء استخدام دواء داسيبتون</p><p dir="RTL">-&nbsp;إذا&nbsp;كنت مسناً أو ضعيفاً</p><p dir="RTL">-&nbsp;عندما يتسبب الآبومورفين الشعور بالنعاس أثناء القيادة أو تشغيل الماكينات بما في ذلك نوبات مفاجئة للنوم (يجب عليك عدم قيادة السيارة أو تشغيل الماكينات إذا كان داسيبتون يجعلك تشعر بالنعاس)</p><p dir="RTL">-&nbsp;يجب أن يتابع طبيبك حالتك بصورة منتظمة عند تعاطي دواء داسيبتون مع دواء ليفوبودا (علاج آخر لمرض باركنسون).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لاحظت أنت أو عائلتك / مقدم الرعاية أنك قد تعاني من حوافز أو رغبة شديدة في التصرف بطرق غير معتادة بالنسبة لك، وأنت لا تستطيع مقاومة الدافع أو الحافز أو الميل للقيام بأنشطة معينة يمكن أن تؤذي نفسك أو الآخرين.&nbsp;وتسمى هذه الاضطرابات باضطرابات التحكم في الاندفاع ويمكن أن تشمل السلوكيات مثل المغامرة الإدمانية أو الأكل المفرط أو الإنفاق، أو الدافع الجنسي غير الطبيعي أو زيادة في الأفكار أو المشاعر الجنسية.&nbsp;قد يحتاج طبيبك بهذه الحالة إلى ضبط الجرعة أو إيقافها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يصاب بعض المرضى بأعراض تشبه الإدمان مما يؤدي إلى الرغبة في تناول جرعات كبيرة داسيبتون وأدوية أخرى تستخدم لعلاج مرض باركنسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك، يرجى إبلاغ الطبيب أو الممرض بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استشر طبيبك أو الصيدلاني قبل تناول الدواء في الحالات التالية:</strong></p><p dir="RTL">إذا كنت تستخدم أدوية معروفة تؤثر على طريقة دقات قلبك.&nbsp;وهذا يشمل الأدوية المستخدمة في مشاكل نبضات القلب (مثل الكينيدين والأميودارون)، والاكتئاب (بما في ذلك مضادات الاكتئاب ثلاثية الحلقات مثل&nbsp;أميتريبتيلين&nbsp;وإيميبرامين)&nbsp;والالتهابات البكتيرية (المضادات الحيوية&nbsp;&quot;ماكرولايد&quot;&nbsp;مثل الازيثروميسين وكلاريثومسين ودومبيرودن.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية</strong>&nbsp;<strong>أخرى</strong> <strong>ودواء داسيبتون 5 ملغ / مل</strong></p><p dir="RTL">اخبر طبيبك&nbsp;أو&nbsp;الصيدلاني&nbsp;إذا كنت تتناول أو&nbsp;قد تناولت مؤخراً&nbsp;أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تستخدم دواء داسيبتون&nbsp;5&nbsp;ملغ / مل مع أدوية أخرى، فربما يتغير تأثير تلك الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وهذا&nbsp;ينطبق&nbsp;بشكل&nbsp;خاص على&nbsp;ما يأتي:</p><p dir="RTL">- أدوية مثل كلوزابين لعلاج بعض الاضطرابات النفسية</p><p dir="RTL">-&nbsp;أدوية لخفض ضغط الدم لديك</p><p dir="RTL">-&nbsp;أدوية أخرى لمرض باركنسون</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك في حال كنت بحاجة إلى&nbsp;ضبط&nbsp;الجرعة من&nbsp;آبومورفين&nbsp;الخاص بك&nbsp;أو أي من أدويتك الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول دواء ليفودوبا (دواء آخر لمرض باركنسون) وكذلك&nbsp;آبومورفين&nbsp;فيجب أن بتابع طبيبك فحص الدم بانتظام.</p><p dir="RTL">&nbsp;<strong>&nbsp;</strong></p><p dir="RTL"><strong>دواء داسيبتون 5</strong>&nbsp;<strong>ملغ / مل</strong>&nbsp;<strong>مع الطعام والشراب</strong></p><p dir="RTL">لا يؤثر الطعام والشراب على&nbsp;داسيبتون&nbsp;5 ملغم / مل</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو في طور الرضاعة الطبيعية، أو تعتقدين أنك حاملاً أو تعتزمين إنجاب أطفال، فعليكِ استشارة طبيبك&nbsp;&lt; الممرض&gt;&nbsp;أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي أن&nbsp;يستخدم&nbsp;دواء داسيبتون&nbsp;5&nbsp;ملغ / مل&nbsp;أثناء الحمل&nbsp;ما لم تكن هناك&nbsp;ضرورة واضحة&nbsp;لذلك.&nbsp;استشيري طبيبك&nbsp;&lt;&nbsp;أو الممرض&nbsp;&gt;&nbsp;قبل استخدام&nbsp;دواء داسيبتون&nbsp;5 ملغ / مل&nbsp;إذا كنت حاملاً، أو تعتقدين أنك قد&nbsp;تكوني&nbsp;حاملاً أو تخططي للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان&nbsp;داسيبتون&nbsp;5 ملغ / مل&nbsp;قد يتنقل إلى حليب الثدي.&nbsp;استشري طبيبك إذا كنت ترضعين رضاعة طبيعية أو تنوين الرضاعة الطبيعية.&nbsp;سوف يشرح لك الطبيب فيما إذا كان ينبغي عليك الاستمرار&nbsp;/&nbsp;التوقف عن الرضاعة الطبيعية أو الاستمرار&nbsp;/&nbsp;التوقف عن تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب دواء داسيبتون&nbsp;5 ملغ / مل&nbsp;النعاس ورغبة قوية في النوم.&nbsp;لا تقود السيارة&nbsp;أو تستخدم أي أدوات أو&nbsp;ماكينات إذا كان&nbsp;دواء داسيبتون&nbsp;5 ملغ / مل&nbsp;يجعلك تشعر بالنعاس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">داسيبتون 5&nbsp;ملغ / مل&nbsp;يحتوي على&nbsp;ميتابيسولفيت الصوديوم&nbsp;والتي&nbsp;قد&nbsp;تسبب&nbsp;تفاعلات&nbsp;فرط الحساسية&nbsp;الشديدة&nbsp;مع&nbsp;تشنج قصبي&nbsp;وأعراض مثل الطفح الجلدي أو حكة في الجلد وصعوبة في التنفس وانتفاخ الجفون والوجه أو الشفتين، وتورم أو احمرار اللسان.&nbsp;إذا تعرضت لهذه الآثار الجانبية، فعليك زيارة أقرب مستشفى.</p><p dir="RTL">&nbsp;</p><p>يحتوي دواء ديسبتون&nbsp;5&nbsp;ملغ / مل&nbsp;على&nbsp;3.4 مغم من&nbsp;الصوديوم&nbsp;لكل&nbsp;ملليتر، وعلى المرضى ممن يحافظون على حمية&nbsp;الصوديوم الخاضعة للمراقبة أخذ ذلك بعين الاعتبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم هذا الدواء&nbsp;إلا وفقاً لتعليمات طبيبك الدقيقة، واستشر طبيبك&nbsp;&lt;ممرضك&gt;&nbsp;أو الصيدلاني إن كانت لديك شكوك بخصوصه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل أن تستخدم &lt;آبومورفين&gt;، سيضمن لك الطبيب أنك تتحمل هذا الدواء ودواء مضاد للقىء تحتاج إلى استخدامه في آن واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم</strong>&nbsp;<strong>دايسبتون</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong>&nbsp;<strong>إذا في الحالات التالية: </strong></p><p dir="RTL">-&nbsp;تحول لون المحلول إلى الأخضر.</p><p dir="RTL">-&nbsp;تعكر المحلول أو ملاحظة وجود جسيمات غريبة فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مكان حقن دواء داسيبتون</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong></p><p dir="RTL">قم بحقن دواء داسيبتون&nbsp;5&nbsp;ملغ / مل&nbsp;في منطقة تحت الجلد بحسب تعليمات طبيبك &lt;&nbsp;أو ممرضك&nbsp;&gt;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عدم حقن</strong>&nbsp;<strong>داستبورن</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong>&nbsp;<strong>في الوريد</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كمية الاستخدام</strong></p><p dir="RTL">الكمية&nbsp;من محلول داسيبتون 5&nbsp;ملغ / مل&nbsp;وإجمالي عدد الجرعات التي يجب أخذها من الدواء يومياً ستعتمد على احتياجاتك الشخصية،&nbsp;وسوف يناقش طبيبك هذا معك ويخبرك عن حجم الجرعة من هذا الدواء التي يجب عليك&nbsp;أخذها.</p><p dir="RTL">سيتم تحديد حجم الجرعة التي تناسبك تماماً خلال زيارتك للعيادة المتخصصة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- متوسط&nbsp;ضخ&nbsp;الجرعة&nbsp;لكل ساعة&nbsp;هو ما بين 1-4 ملغ&nbsp;آبومورفين هيدروكلوريد.</p><p dir="RTL">-&nbsp;يتم إعطاؤك هذه الجرعة عادة أثناء فترة استيقاظك وتتوقف بشكل عام&nbsp;قبل النوم.</p><p dir="RTL">-&nbsp;يجب أن لا تتجاوز كمية الآبومورفين هيدروكلوريد التي تتلقاها يومياً 100 ملغ.</p><p dir="RTL">-&nbsp;سيحدد&nbsp;الطبيب&nbsp;&lt;&nbsp;أو الممرض&nbsp;&gt;&nbsp;الجرعة الأفضل لك.</p><p dir="RTL">-&nbsp;يجب استخدام مكان مختلف لكل عملية ضخ كل 12 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليست هناك حاجة لتخفيف داسيبتون قبل الاستخدام،&nbsp;ولا ينبغي كذلك أن يُخلط مع أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم تصميم داسيبتون من أجل التسريب المستمر بواسطة مضخة صغيرة أو حقنة&nbsp;ولا يجوز استخدامه للحقن المتقطع.&nbsp;اختيار استخدام المضخة الصغيرة و/أو الحقنة وإعدادات الجرعة المطلوبة سيحددها الطبيب وفقاً للاحتياجات الخاصة للمريض.</p><p dir="RTL"><strong>&nbsp;</strong>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى&nbsp;حول&nbsp;استخدام هذا الدواء، استشر طبيبك&nbsp;&lt;&nbsp;أو&nbsp;ممرضك&nbsp;&gt;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالات استخدام دواء داسيبتون</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong>&nbsp;<strong>أكثر مما ينبغي: </strong></p><p dir="RTL">-&nbsp;أخبر طبيبك أو اتصل بأقرب قسم للطوارئ في المستشفى على الفور.</p><p dir="RTL">-&nbsp;من الضروري تناول الجرعة الصحيحة من داسيبتون وعدم استخدام كمية أكبر من الموصى بها من الطبيب.&nbsp;الجرعات العالية قد تؤدي إلى بطء معدل ضربات القلب وحالة مرضية شديدة ونعاس شديد و/أو صعوبة في التنفس.&nbsp;قد تشعر أيضاً بالإغماء أو بالدوار خاصة عند الوقوف بسبب انخفاض ضغط الدم.&nbsp;الاستلقاء ورفع قدميك&nbsp;سيساعد على علاج انخفاض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان استخدام</strong>&nbsp;<strong>داسيبتون</strong>&nbsp;<strong>5 ملغ / مل</strong></p><p dir="RTL">إذا نسيت تناول العلاج خذه عندما تحتاجه إليه في المرة القادمة، ولا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقفك عن استخدام</strong>&nbsp;<strong>داسيبتون</strong><strong> </strong><strong>5</strong>&nbsp;<strong>ملغ / مل</strong></p><p dir="RTL">اتصل بطبيبك قبل التوقف عن العلاج واستشره فيما إذا كان هذا مناسباً أم لا&nbsp;.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، استشر طبيبك&nbsp;&lt;ممرضك&gt;&nbsp;أو الصيدلاني.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء أعراضاً جانبية شأنه في ذلك شأن جميع العقاقير الأخرى، رغم أنها لا تصيب الجميع ممن يتناولون هذه الأدوية.&nbsp;اتصل بطبيبك إذا كنت تعتقد أن دواءك يجعلك تشعر بتوعك أو إذا أصابك عرض من الأعراض الآتية:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>آثار جانبية&nbsp;شائعة جداً&nbsp;(قد تظهر على أكثر من مريض واحد من بين عشرة مرضى):</u></p><p dir="RTL">-&nbsp;تقرحات تحت الجلد في موقع الحقن والتي هي بمثابة تقرح ومثيرة للقلق وربما تكون حمراء اللون مع حكة.&nbsp;من أجل تفادي هذه التقرحات، فمن المستحسن تغيير موقع الحقن في كل مرة تقوم فيها بإدخال الإبرة.</p><p dir="RTL"><strong>-</strong>&nbsp;الهلوسة (رؤية أو سماع أو شعور أشياء غير موجودة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>آثار جانبية&nbsp;شائعة&nbsp;(قد تظهر على مريض واحد من بين عشرة مرضى):</u></p><p dir="RTL">الشعور بالمرض أو التوعك، خاصة عند البدء باستخدام دواء داسيبتون&nbsp;5 ملغ / مل.&nbsp;يجب البدء بأخذ دواء دومبيريدون&nbsp;قبل يومين على الأقل من تناول دواء داسيبتون 5&nbsp;مغم / مل&nbsp;لتجنب الشعور بالحالة المرضية أو التوعك.</p><p dir="RTL">-&nbsp;إذا كنت تتعاطى دواء دومبيريدون وما زلت تشعر بالغثيان، أو إذا كنت لا تأخذ دومبيريدون وأنت&nbsp;مصاب بالمرض، استشر طبيبك&nbsp;&lt;&nbsp;ممرضك&gt; فوراً.</p><p dir="RTL">-&nbsp;الشعور بالتعب أو&nbsp;النعاس الشديد</p><p dir="RTL">-&nbsp;الارتباك أو الهلوسة</p><p dir="RTL">-&nbsp;التثاؤب</p><p dir="RTL">-&nbsp;الشعور بالدوخة أو دوّار خفيف عند الوقوف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>آثار جانبية&nbsp;غير مألوفة&nbsp;(قد تظهر على مريض واحد من بين مئة مريض):</u></p><p dir="RTL">- زيادة الحركات اللاإرادية أو زيادة الاهتزاز خلال فترات تعاطي الدواء.</p><p dir="RTL">-&nbsp;فقر الدم الانحلالي وانهيار غير طبيعي لخلايا الدم الحمراء في الأوعية الدموية أو في أي مكان آخر في الجسم.&nbsp;هذا هو أحد الآثار الجانبية غير الشائعة التي يمكن أن تظهر على المرضى الذين يتناولون عقار ليفودوبا.</p><p dir="RTL">-&nbsp;النوم المفاجئ</p><p dir="RTL">-&nbsp;الطفح الجلدي</p><p dir="RTL">-&nbsp;صعوبات في التنفس</p><p dir="RTL">-&nbsp;تقرحات في موقع الحقن</p><p dir="RTL">-&nbsp;انخفاض في خلايا الدم الحمراء التي قد تجعل لون الجلد أصفراً شاحباً وتسبب ضعف أو ضيق في التنفس</p><p dir="RTL">-&nbsp;انخفاض في الصفائح الدموية مما يزيد من خطر النزيف أو الكدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>آثار جانبية&nbsp;نادرة&nbsp;(قد تظهر على مريض واحد من بين ألف مريض):</u></p><p dir="RTL">-&nbsp;رد فعل تحسسي&nbsp;كصعوبة التنفس أو ضيق الصدر وانتفاخ الجفون والوجه أو الشفتين وتورم أو احمرار اللسان.</p><p dir="RTL">-&nbsp;فرط الخلايا الحمضية، وهي كمية غير طبيعية عالية من خلايا الدم البيضاء في الدم أو في أنسجة الجسم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>آثار جانبية&nbsp;بتواتر غير معروف (لا يمكن تقدير التواتر من البيانات المتاحة):</u></p><p dir="RTL">-&nbsp;تورم الساقين والقدمين أو الأصابع.</p><p dir="RTL">-&nbsp;إغماء.</p><p dir="RTL">-&nbsp;العدوان والاهتياج.</p><p dir="RTL">-&nbsp;عدم القدرة على مقاومة الاندفاع أو الميل لارتكاب فعل قد يكون ضاراً بك أو بالآخرين، والذي قد يشمل ما يأتي:&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دافع قوي للمغامرة المفرطة على الرغم من العواقب الشخصية أو العائلية الخطيرة.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتمام أو سلوك جنسي متغير أو متزايد بنفسك أو بالآخرين كزيادة الدافع الجنسي على سبيل المثال.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التسوق المفرط أو الانفاق غير المنضبط.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشراهة في تناول الطعام (تناول كميات كبيرة من الطعام في فترة زمنية قصيرة) أو تناول الطعام القهري (تناول المزيد من الطعام أكثر من المعتاد وأكثر مما يلزم لإشباع جوعك).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك إذا واجهت أي من السلوكيات التالية، فسوف يناقش هو أو هي&nbsp; سبل التعامل مع الأعراض أو الحد منها</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">اذا تعرضت لأي آثار جانبية اتصل بطبيبك&nbsp;&lt;ممرضك&gt;&nbsp;أو&nbsp;الصيدلاني، وهذا يتضمن أي آثار جانبية غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية اتصل بطبيبك أو الصيدلاني &lt;أو الممرض&gt;، وهذا يتضمن أي&nbsp;آثار جانبية&nbsp;محتملة&nbsp;غير مدرجة في هذه النشرة.&nbsp;يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة عن طريق:</p><p dir="RTL"><strong>المملكة العربية السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19999</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الالكتروني npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الالكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;دول مجلس التعاون الخليجي الأخرى: يرجى الاتصال بالجهات المختصة ذات الصلة</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ&nbsp;هذا الدواء&nbsp;بعيداً عن&nbsp;متناول&nbsp;الأطفال.</p><p dir="RTL">احفظ القارورة&nbsp;في&nbsp;الكرتون&nbsp;الخارجي من&nbsp;أجل حمايتها من الضوء.</p><p dir="RTL">لا تعمل على تبريد أو تجميد القارورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد فتح وملئ المنتج الدوائي في المحاقن الملحقة بمجموعات التسريب الوريدي: تم إثبات استقرار الاستخدام الكيميائي والفيزيائي لمدة 7 أيام عند 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، يجب استخدام المنتج على الفور ما لم تكن طريقة الفتح والتعامل مع الدواء تمنع خطر التلوث الجرثومي.&nbsp;إذا لم يتم استخدام الدواء على الفور، فإن أوقات وشروط التخزين أثناء الاستخدام تقع على عاتق المستخدم&nbsp;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم&nbsp;هذا الدواء&nbsp;بعد تاريخ انتهاء الصلاحية الموضح على العلبة والكرتون، ويشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم&nbsp;هذا الدواء&nbsp;إذا&nbsp;لاحظت&nbsp;أن&nbsp;المحلول قد تحول إلى اللون الأخضر.&nbsp;يجب استخدامه فقط إذا كان المحلول&nbsp;صافياً وعديم اللون&nbsp;ومائلاً قليلاً إلى اللون الأصفر وخاليًا من الجسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب&nbsp;التخلص من المحاقن&nbsp;والإبر&nbsp;المستخدمة&nbsp;ضمن صندوق نفايات صلب أو حاويات مناسبة.&nbsp;عندما يكون صندوق النفايات لديك أو الحاوية ممتلئة، يُرجى تسليمه إلى طبيبك أو الصيدلاني للتخلص منه بصورة آمنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.&nbsp;اسأل الصيدلاني عن كيفية&nbsp;التخلص من&nbsp;الأدوية&nbsp;التي&nbsp;لم تعد&nbsp;تستخدمها حيث&nbsp;من شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات داسيبتون</strong>&nbsp;<strong>5</strong>&nbsp;<strong>ملغ / مل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة&nbsp;الفعالة&nbsp;هي آبومورفين هيدروكلوريد&nbsp;هيميهيدريت.&nbsp;كل&nbsp;مليلتر&nbsp;من&nbsp;ديسبتون&nbsp;5&nbsp;ملغ / مل&nbsp;يحتوي على&nbsp;5&nbsp;ملغ&nbsp;من&nbsp;آبومورفين&nbsp;هيدروكلوريد&nbsp;هيميهيدريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">داسيبتون&nbsp;5&nbsp;ملغ / مل متاح في&nbsp;قارورة سعة 20&nbsp;مل&nbsp; تحتوي على&nbsp;100 ملغ&nbsp;من&nbsp;آبومورفين&nbsp;هيدروكلوريد&nbsp;هيميهيدريت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى:</p><p dir="RTL">-&nbsp;ميتابيسولفيت الصوديوم (E223)</p><p dir="RTL">-&nbsp;كلوريد الصوديوم</p><p dir="RTL">-&nbsp;حامض الهيدروكلوريك&nbsp;(&nbsp;لضبط درجة الحموضة&nbsp;)</p><p dir="RTL">-&nbsp;ماء مخصص للحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى الرجوع إلى&nbsp;القسم رقم 2:&nbsp;داسيبتون&nbsp;5&nbsp;ملغ / مل&nbsp;يحتوي على ميتابيسولفيت وكلوريد الصوديوم&nbsp;&quot;فيما يتعلق بميتابيسولفيت الصوديوم وكلوريد الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">داسيبتون&nbsp;5&nbsp;ملغ / مل&nbsp;هو محلول صافٍ وعديم اللون ومائل إلى&nbsp;اللون الأصفر&nbsp;قليلاً&nbsp;لأغراض التسريب الوريدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قوارير&nbsp;زجاجية&nbsp;تحتوي على&nbsp;محلول 20&nbsp;مل&nbsp;للتسريب الوريدي ضمن مجموعات تتكون إما من قارورة واحدة أو خمسة قوارير أو 30 قارورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">العبوات:&nbsp;5 &times; 1 ، 10 &times; 1 ، 30 &times; 1 ،&nbsp;2 &times; 5 و 6 &times; 5</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong></p><p dir="RTL">EVER Neuro Pharma GmbH</p><p dir="RTL">Oberburgau 3</p><p dir="RTL">Unterach 4866</p><p dir="RTL">النمسا</p><p dir="RTL"><strong>الجهة الصانعة </strong></p><p dir="RTL">EVER Neuro Pharma GmbH</p><p dir="RTL">Oberburgau 3</p><p dir="RTL">Unterach 4866</p><p dir="RTL">النمسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">EVER Pharma Jena GmbH</p><p dir="RTL">Otto-Schott-Strasse 15</p><p dir="RTL">07745</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تنقيح هذه النشرة للمرة الأخيرة بتاريخ سبتمبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dacepton 5 mg/ml Solution for infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 5 mg apomorphine hydrochloride hemihydrate

20 ml contain 100 mg apomorphine hydrochloride hemihydrate

Excipient with known effect:
Sodium metabisulphite (E223) 1 mg per ml
Sodium chloride 8 mg per ml

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion
Clear and colourless to slightly yellow solution, free from visible particles 
pH of 3.3 – 4.0. 
Osmolality: 290 mOsm/kg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Treatment of motor fluctuations (&ldquo;on-off&rdquo; phenomena) in patients with Parkinson&#39;s disease which are not sufficiently controlled by oral anti-Parkinson medication.</p><p dir="ltr"><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong><em>Selection of Patients suitable for Dacepton 5 mg/ml solution for infusion:</em></strong></p><p dir="ltr">Patients selected for treatment with Dacepton 5 mg/ml solution for infusion should be able to recognise the onset of their &rdquo;off&rdquo; symptoms and be capable of injecting themselves or else have a responsible carer able to inject for them when required.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients treated with apomorphine will usually need to start domperidone at least two days prior to initiation of therapy. The domperidone dose should be titrated to the lowest effective dose and discontinued as soon as possible. Before the decision to initiate domperidone and apomorphine treatment, risk factors for QT interval prolongation in the individual patient should be carefully assessed to ensure that the benefit outweighs the risk (see section 4.4).</p><p dir="ltr">Apomorphine should be initiated in the controlled environment of a specialist clinic. The patient should be supervised by a physician experienced in the treatment of Parkinson&#39;s disease (e.g. neurologist). The patient&#39;s treatment with levodopa, with or without dopamine agonists, should be optimised before starting treatment with Dacepton 5 mg/ml solution for infusion.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Adults</u></strong></p><p dir="ltr"><strong><u>&nbsp;</u></strong></p><p dir="ltr"><strong><u>Method of administration</u></strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml solution for infusion is a pre-diluted vial intended for use without dilution for subcutaneous use and to be administered as a continuous subcutaneous infusion by minipump and/or syringe-driver (see section 6.6). It is not intended to be used for intermittent injection.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Apomorphine must not be used via the intravenous route.</u></strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not use if the solution has turned green. The solution should be inspected visually prior to use. Only clear, colourless to slightly yellow and particle free solution should be used.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Posology</u></strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Continuous Infusion</em></strong></p><p dir="ltr">Patients who have shown a good &ldquo;on&rdquo; period response during the initiation stage of apomorphine therapy, but whose overall control remains unsatisfactory using intermittent injections, or who require many and frequent injections (more than 10 per day), may be commenced on or transferred to continuous subcutaneous infusion by minipump and/or syringe-driver as follows:</p><p dir="ltr">&nbsp;</p><p dir="ltr">The choice, of which minipump and / or syringe-driver to use, and the dosage settings required, will be determined by the physician in accordance with the particular needs of the patient.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Determination of Threshold Dose</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">The threshold dose for continuous infusion should be determined as follows: Continuous infusion is started at a rate of 1 mg apomorphine hydrochloride hemihydrate (0.2 ml) per hour then increased according to the individual response each day. Increases in the infusion rate should not exceed 0.5 mg at intervals of not less than 4 hours. Hourly infusion rates may range between 1 mg and 4 mg (0.2 ml and 0.8 ml), equivalent to 0.014 - 0.06 mg/kg/hour. Infusions should run for waking hours only. Unless the patient is experiencing severe night-time problems, 24 hour infusions are not advised. Tolerance to the therapy does not seem to occur as long as there is an overnight period without treatment of at least 4 hours. In any event, the infusion site should be changed every 12 hours.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients may need to supplement their continuous infusion with intermittent bolus boosts, as necessary, and as directed by their physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr">A reduction in dosage of other dopamine agonists may be considered during continuous infusion.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Establishment of treatment</em></strong></p><p dir="ltr">Alterations in dosage may be made according to the patient&#39;s response.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The optimal dosage of apomorphine hydrochloride hemihydrate varies between individuals but, once established, remains relatively constant for each patient.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><em>Precautions on continuing treatment</em></strong></p><p dir="ltr">The daily dose of Dacepton 5 mg/ml solution for infusion varies widely between patients, typically within the range of 3-30 mg.</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is recommended that the total daily dose of apomorphine hydrochloride hemihydrate should not exceed 100 mg.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical studies it has usually been possible to make some reduction in the dose of levodopa; this effect varies considerably between patients and needs to be carefully managed by an experienced physician.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Once treatment has been established, domperidone therapy may be gradually reduced in some patients but successfully eliminated only in a few, without any vomiting or hypotension.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Paediatric population</u></strong></p><p dir="ltr">Dacepton 5 mg/ml solution for infusion is contraindicated for children and adolescents under 18 years of age (see section 4.3).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Elderly</u></strong></p><p dir="ltr">The elderly are well represented in the population of patients with Parkinson&#39;s disease and constitute a high proportion of those studied in clinical trials of apomorphine. The management of elderly patients treated with apomorphine has not differed from that of younger patients. However, extra caution is recommended during initiation of therapy in elderly patients because of the risk of postural hypotension.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>Renal impairment</u></strong></p><p dir="ltr">A dose schedule similar to that recommended for adults, and the elderly, can be followed for patients with renal impairment (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

In patients with respiratory depression, dementia, psychotic diseases or hepatic insufficiency.

Apomorphine hydrochloride hemihydrate treatment must not be administered to patients who have an “on” response to levodopa which is marred by severe dyskinesia or dystonia.



Dacepton 5 mg/ml solution for infusion is contraindicated for children and adolescents under 18 years of age.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Apomorphine hydrochloride hemihydrate should be given with caution to patients with renal, pulmonary or cardiovascular disease and persons prone to nausea and vomiting.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Extra caution is recommended during initiation of therapy in elderly and/or debilitated patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Since apomorphine may produce hypotension, even when given with domperidone pre-treatment, care should be exercised in patients with pre-existing cardiac disease or in patients taking vasoactive medicinal products such as antihypertensives, and especially in patients with pre-existing postural hypotension.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Since apomorphine, especially at high dose, may have the potential for QT prolongation, caution should be exercised when treating patients at risk for torsades de pointes arrhythmia.</p><p dir="ltr">When used in combination with domperidone, risk factors in the individual patient should be carefully assessed. This should be done before treatment initiation, and during treatment. Important risk factors include serious underlying heart conditions such as congestive cardiac failure, severe hepatic impairment or significant electrolyte disturbance. Also medication possibly affecting electrolyte balance, CYP3A4 metabolism or QT interval should be assessed. Monitoring for an effect on the QTc interval is advisable. An ECG should be performed:</p><p dir="ltr">- prior to treatment with domperidone</p><p dir="ltr">- during the treatment initiation phase</p><p dir="ltr">- as clinically indicated thereafter</p><p dir="ltr">The patient should be instructed to report possible cardiac symptoms including palpitations, syncope, or near-syncope. They should also report clinical changes that could lead to hypokalaemia, such as gastroenteritis or the initiation of diuretic therapy.</p><p dir="ltr">At each medical visit, risk factors should be revisited.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Apomorphine is associated with local subcutaneous effects. These can sometimes be reduced by the rotation of injection sites or possibly by the use of ultrasound (if available) in order to avoid areas of nodularity and induration.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Haemolytic anaemia and thrombocytopenia have been reported in patients treated with apomorphine. Haematology tests should be undertaken at regular intervals as with levodopa, when given concomitantly with apomorphine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Caution is advised when combining apomorphine with other medicinal products, especially those with a narrow therapeutic range (see Section 4.5).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neuropsychiatric problems co-exist in many patients with advanced Parkinson&#39;s disease. There is evidence that for some patients neuropsychiatric disturbances may be exacerbated by apomorphine. Special care should be exercised when apomorphine is used in these patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Apomorphine has been associated with somnolence, and episodes of sudden sleep onset, particularly in patients with Parkinson&#39;s disease. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with apomorphine. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore, a reduction of dosage or termination of therapy may be considered.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&nbsp;Impulse control disorders</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including apomorphine. Dose reduction/tapered discontinuation should be considered if such symptoms develop.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dopamine dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with apomorphine. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml solution for infusion contains sodium metabisulphite which may rarely cause severe hypersensitivity reactions and bronchospasm.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Dacepton 5 mg/ml contains 3.4 mg sodium per ml. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Patients selected for treatment with apomorphine hydrochloride hemihydrate are almost certain to be taking concomitant medications for their Parkinson&#39;s disease. In the initial stages of apomorphine hydrochloride hemihydrate therapy, the patient should be monitored for unusual side-effects or signs of potentiation of effect.</p><p dir="ltr">Neuroleptic medicinal products may have an antagonistic effect if used with apomorphine. There is a potential interaction between clozapine and apomorphine, however clozapine may also be used to reduce the symptoms of neuropsychiatric complications.</p><p dir="ltr">If neuroleptic medicinal products have to be used in patients with Parkinson&#39;s disease treated by dopamine agonists, a gradual reduction in apomorphine dose may be considered when administration is by minipump and or syringe-driver (symptoms suggestive of neuroleptic malignant syndrome have been reported rarely with abrupt withdrawal of dopaminergic therapy).</p><p dir="ltr">&nbsp;</p><p dir="ltr">The possible effects of apomorphine on the plasma concentrations of other medicinal products have not been studied. Therefore caution is advised when combining apomorphine with other medicinal products, especially those with a narrow therapeutic range.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Antihypertensive and Cardiac Active Medicinal Products</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Even when co-administered with domperidone, apomorphine may potentiate the antihypertensive effects of these medicinal products (see Section 4.4)</p><p dir="ltr">&nbsp;</p><p dir="ltr">It is recommended to avoid the administration of apomorphine with other drugs known to prolong the QT interval.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>Pregnancy</em></p><p dir="ltr">There is no experience of apomorphine usage in pregnant women.</p><p dir="ltr">Animal reproduction studies do not indicate any teratogenic effects, but doses given to rats which are toxic to the mother can lead to failure to breathe in the newborn. The potential risk for humans is unknown. See Section 5.3.</p><p dir="ltr">Dacepton 5 mg/ml solution for infusion should not be used during pregnancy unless clearly necessary</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Breast-feeding</em></p><p dir="ltr">It is not known whether apomorphine is excreted in breast milk. A decision on whether to continue/discontinue breastfeeding or to continue/discontinue therapy with Dacepton 5 mg/ml solution for infusion should be made taking into account the benefit of breast-feeding to the child and the benefit of Dacepton 5 mg/ml solution for infusion to the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Apomorphine hydrochloride hemihydrate has minor or moderate influence on the ability to drive and use machines.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Patients being treated with apomorphine and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities (e.g. operating machines) where impaired alertness may put themselves or others at risk of serious injury or death until such recurrent episodes and somnolence have resolved (see also section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:577px"><tbody><tr><td style="vertical-align:top"><p>Very common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(&ge;1/10)</p></td></tr><tr><td style="vertical-align:top"><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/100 to &lt;1/10)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/1,000 to &lt;1/100)</p></td></tr><tr><td style="vertical-align:top"><p>Rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/10,000 to &lt;1/1,000)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;1/10,000)</p></td></tr><tr><td style="vertical-align:top"><p>Not known:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (cannot be estimated from the available data)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr" style="width:577px"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Uncommon:</em></strong></p><p>Haemolytic anaemia and thrombocytopenia have been reported in patients treated with apomorphine.</p><p><strong><em>Rare:</em></strong></p><p>Eosinophilia has rarely occurred during treatment with apomorphine hydrochloride hemihydrate.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Rare: </em></strong></p><p>Due to the presence of sodium metabisulphite, allergic reactions (including anaphylaxis and bronchospasm) may occur.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Very common:</em></strong></p><p>Hallucinations</p><p><strong><em>Common:</em></strong></p><p>Neuropsychiatric disturbances (including transient mild confusion and visual hallucinations) have occurred during apomorphine hydrochloride hemihydrate therapy.</p><p><strong><em>Not known: </em></strong></p><p><strong>Impulse control disorders:</strong></p><p>Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists including apomorphine (see section 4.4).</p><p>Aggression, agitation.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Common: </em></strong></p><p>Transient sedation with each dose of apomorphine hydrochloride hemihydrate at the start of therapy may occur; this usually resolves over the first few weeks.</p><p>Apomorphine is associated with somnolence.</p><p>Dizziness / light-headedness have also been reported.</p><p><strong><em>Uncommon:</em></strong></p><p>Apomorphine may induce dyskinesias during &ldquo;on&rdquo; periods which can be severe in some cases, and in a few patients may result in cessation of therapy.</p><p>Apomorphine has been associated with sudden sleep onset episodes. See section 4.4</p><p><strong><em>Unknown:</em></strong></p><p>Syncope</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Uncommon:</em></strong></p><p>Postural hypotension is seen infrequently and is usually transient (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Common:</em></strong></p><p>Yawning has been reported during apomorphine therapy</p><p><strong><em>Uncommon: </em></strong></p><p>Breathing difficulties have been reported.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Common: </em></strong></p><p>Nausea and vomiting, particularly when apomorphine treatment is first initiated, usually as a result of the omission of domperidone (See section 4.2).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><em>Uncommon:</em></strong></p><p>Local and generalised rashes have been reported.</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong><em>Very common:</em></strong></p><p>Most patients experience injection site reactions, particularly with continuous use. These may include subcutaneous nodules, induration, erythema, tenderness and panniculitis. Various other local reactions (such as irritation, itching, bruising and pain) may also occur.</p><p><strong><em>Uncommon:</em></strong></p><p>Injection site necrosis and ulceration have been reported</p><p><strong><em>Not Known:</em></strong></p><p>Peripheral oedema has been reported.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong><em>Uncommon:</em></strong><em> </em></p><p>Positive Coombs&#39; tests have been reported for patients receiving apomorphine.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Reporting of suspected adverse reactions</u></p><p dir="ltr">Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Pharmacovigilance Centre (NPC):</p><p dir="ltr">- SFDA Call Center: 19999</p><p dir="ltr">- E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">- Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">There is little clinical experience of overdose with apomorphine by this route of administration. Symptoms of overdose may be treated empirically as suggested below:</p><p dir="ltr">&nbsp;</p><p dir="ltr">Excessive emesis may be treated with domperidone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Respiratory depression may be treated with naloxone.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hypotension: appropriate measures should be taken, e.g. raising the foot of the bed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bradycardia may be treated with atropine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Anti-Parkinson drugs, dopamine agonists, ATC code: N04B C07</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Although in intact experimental animals, administration of apomorphine suppresses the rate of firing of nigro-striatal cells and in low dose has been found to produce a reduction in locomotor activity (thought to represent pre-synaptic inhibition of endogenous dopamine release) its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites. This biphasic effect is also seen in humans.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">After subcutaneous injection of apomorphine its fate can be described by a two-compartment model, with a distribution half-life of 5 (&plusmn;1.1) minutes and an elimination half-life of 33 (&plusmn;3.9) minutes. Clinical response correlates well with levels of apomorphine in the cerebrospinal fluid; the active substance distribution being best described by a two-compartment model. Apomorphine is rapidly and completely absorbed from subcutaneous tissue, correlating with the rapid onset of clinical effects (4-12 minutes), and that the brief duration of clinical action of the active substance (about 1 hour) is explained by its rapid clearance. The metabolism of apomorphine is by glucuronidation and sulphonation to at least ten per cent of the total; other pathways have not been described.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Repeat dose subcutaneous toxicity studies reveal no special hazard for humans, beyond the information included in other sections of the SmPC.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>In vitro</em> genotoxicity studies demonstrated mutagenic and clastogenic effects, most likely due to products formed by oxidation of apomorphine. However, apomorphine was not genotoxic in the <em>in vivo</em> studies performed.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The effect of apomorphine on reproduction has been investigated in rats. Apomorphine was not teratogenic in this species, but it was noted that doses which are toxic to the mother can cause loss of maternal care and failure to breathe in the newborn.</p><p dir="ltr">&nbsp;</p><p dir="ltr">No carcinogenicity studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium metabisulphite (E223)</p><p>Sodium chloride</p><p>Hydrochloric acid (for pH-adjustment)</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened: 36 months 

After opening and filling the drug product in syringes attached with infusion sets: chemical and physical in-use stability has been demonstrated for 7 days at 25 °C. From a microbiological point of view, unless the method of opening and further handling precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.


Single use only.
Discard any unused contents 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Keep the vials in the outer carton in order to protect from light.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Do not refrigerate or freeze.</p><p dir="ltr">&nbsp;</p><p dir="ltr">For storage conditions after first opening of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Clear glass vials, type I with bromobutyl rubber stopper and a flip-off cap, containing 20 ml solution for infusion, in packs of 1, 5 or 30 vials.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Bundle packs: 5 x 1, 10 x 1, 30 x 1, 2 x 5 and 6 x 5</p><p dir="ltr">&nbsp;</p><p dir="ltr">Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use if the solution has turned green.</p><p>&nbsp;</p><p>The solution should be inspected visually prior to use. Only clear and colourless to slightly yellow solutions without particles in undamaged containers should be used.</p><p>&nbsp;</p><p>For single use only. Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p><p>&nbsp;</p><p><strong><u>Continuous infusion and the use of a minipump and or syringe-driver</u></strong></p><p>The choice of which minipump and or syringe-driver to use, and the dosage settings required, will be determined by the physician in accordance with the particular needs of the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	EVER Neuro Pharma GmbH
	Oberburgau 3
	4866 Unterach
	Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>